Etrolizumab as Induction Therapy in Moderate to Severe Crohnʼs Disease: Results From BERGAMOT Cohort 1

William, Sandborn; Julian, Panes; Jennifer, J Brady; Hassanali, Azra; Jacob, Robin; Sharafali, Zaineb; Young, Oh; Tole, Swati

doi:10.14309/00000434-201802001-00011

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a completed phase III trial in UC, etrolizumab met its primary endpoint in two induction studies but not in any maintenance studies ( 78 – 81 ). Phase III trials assessing etrolizumab in CD are still ongoing with positive results in an exploratory induction cohort ( 82 ). The clinical efficacy of Etrolizumab may be partially explained by impairing the retention of CD103 + T RM .…”

Section: T Rm and Inflammatory Bowel Diseasementioning

confidence: 99%

An Overview of Tissue-Resident Memory T Cells in the Intestine: From Physiological Functions to Pathological Mechanisms

2022

View full text Add to dashboard Cite

The human intestine contains a complex network of innate and adaptive immune cells that provide protective immunity. The dysfunction of this network may cause various chronic diseases. A large number of T cells in the human intestine have been identified as tissue-resident memory T cells (TRM). TRM are present in the peripheral tissues, and they do not recirculate through the blood. It is known that TRM provide rapid immune responses at the frontline of pathogen invasion. Recent evidence also suggests that these cells play a role in tumor surveillance and the pathogenesis of autoimmune diseases. In this review, we discuss the general features of intestinal TRM together with their role in intestinal infection, colorectal cancer (CRC), and inflammatory bowel disease (IBD).

show abstract

Section: T Rm and Inflammatory Bowel Diseasementioning

confidence: 99%

An Overview of Tissue-Resident Memory T Cells in the Intestine: From Physiological Functions to Pathological Mechanisms

2022

View full text Add to dashboard Cite

show abstract

“…Etrolizumab is now being tested in BERGAMOT, a phase III trial in CD. The proof of concept induction cohort of BERGAMOT in Crohn's compared 105mg 4-weekly or 210mg at weeks 0, 2, 4, 8 and 12 weeks (28). At week 14 there was an improvement in symptoms and endoscopic score.…”

Section: α4β7 Targetingmentioning

confidence: 99%